Ministry Revises 'Regulations on the Handling of Veterinary Pharmaceuticals'

GMP Standards to Be Strengthened Starting with Injectables

Renewal System Introduced for Enhanced Post-Management

The government has decided to strengthen Good Manufacturing Practice (GMP) standards for veterinary pharmaceuticals in accordance with international benchmarks, in order to enhance product quality and boost export competitiveness.


The Ministry of Agriculture, Food and Rural Affairs announced on July 30 that it has revised and promulgated the 'Regulations on the Handling of Veterinary Pharmaceuticals and Other Products' reflecting these changes.


The Asia Business Daily DB

The Asia Business Daily DB

View original image

First, the Ministry will upgrade its GMP requirements to match international standards. GMP is a set of guidelines for controlling manufacturing facilities, processes, and quality to ensure the safe and consistent production of veterinary pharmaceuticals.


An official from the Ministry explained, "Globally, standards for process validation, facility and equipment verification in the veterinary pharmaceutical sector are gradually being reinforced. Accordingly, we aim to incorporate these requirements into Korea's GMP standards so we can produce safer and higher-quality veterinary medicines."


The government will also allow a transition period for the industry to prepare for upgraded standards, such as facility improvements. Veterinary pharmaceuticals will be classified according to product characteristics into the following categories: ▲ Formulation Group 1 (injectables and infusions), ▲ Formulation Group 2 (topical and oral liquids, etc.), and ▲ Formulation Group 3 (biological products and raw materials). The strengthened measures will be introduced in phases, starting with injectables, from 2030 to 2035.


The Ministry also plans to introduce customized GMP standards and overhaul its management system to reflect product-specific characteristics. Previously, standards were only distinguished between general veterinary medicines and biologicals such as vaccines. Going forward, these will be broken down further into six categories—such as finished products and raw materials—with customized standards to match each type and characteristic. This change will be implemented from 2027.


Additionally, the current system that manages at the manufacturing facility unit will shift so that, even within the same facility, manufacturing processes and quality control systems will be aligned according to each product's characteristics. Furthermore, when companies apply for approval of products of the same formulation type at GMP-certified plants—except for some cases such as new drugs and biologicals—submission of GMP-related documents will be exempted, reducing administrative burdens for businesses.


A renewal system will also be introduced to strengthen GMP post-management. Starting in 2027, veterinary pharmaceutical manufacturing facilities will be re-inspected every three years to ensure their GMP standards are continuously maintained. Previously, only one conformity assessment was required upon new facility approval. Now, periodic inspections every three years will confirm ongoing compliance with the standards.



An official from the Ministry stated, "By modernizing GMP for veterinary pharmaceuticals in line with global standards, we expect to raise the credibility of Korea's veterinary pharmaceutical industry and lay the foundation for enhanced export competitiveness. The Ministry will engage in ongoing dialogue and active collaboration with relevant associations and industry stakeholders to ensure the new systems are established smoothly in the field."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing